Pharvaris (PHVS) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.70

Estimate

-$0.65

Surprise

-7.1%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Pharvaris (PHVS) reported a wider loss than forecast — diluted EPS of -$0.70 against the -$0.65 estimate (a 7.1% shortfall).

• RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52 — benzinga, 2026-08-13
• Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40 — benzinga, 2026-08-13
• Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75 — benzinga, 2026-08-13

TrendMatrix currently rates PHVS Sell at 5.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -7.1% surprise compares with a -5.1% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$38.10

Price target

$51.27

Stop

$35.36

Upside to target

+34.6%

Reward-to-risk

3.0:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.67B

P/E (fwd)

-12.1

52-week range

$20.65–$43.25

Off 52-week high

11.9%

RSI (14)

60

Volume vs avg

1.44×

Score today

5.5/10